At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan
In Brief
A Phase 1 clinical trial evaluating Lasmiditan, Alprazolam, and 1 other intervention for Recreational Drug Use and Prescription Drug Abuse (Not Dependent). Completed, enrolled 96 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth). This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.
Study Details
Timeline
Interventions
Administered orally
Administered orally
Administered orally